Maxim Group Analysts Give Celsion Corp. (CLSN) a $4.00 Price Target
Celsion Corp. (NASDAQ:CLSN) received a $4.00 price objective from research analysts at Maxim Group in a research report issued on Tuesday. The firm presently has a a “buy” rating on the stock. Maxim Group’s target price indicates a potential upside of 241.88% from the stock’s current price.
Separately, HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of Celsion Corp. in a research note on Tuesday, July 12th.
Shares of Celsion Corp. (NASDAQ:CLSN) traded down 1.71% during mid-day trading on Tuesday, reaching $1.15. 44,513 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $1.23 and its 200-day moving average price is $1.34. The company’s market capitalization is $29.68 million. Celsion Corp. has a one year low of $1.04 and a one year high of $2.31.
Celsion Corp. (NASDAQ:CLSN) last released its earnings results on Monday, August 15th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. Celsion Corp. had a negative net margin of 3,966.14% and a negative return on equity of 103.07%. On average, equities analysts expect that Celsion Corp. will post ($0.83) earnings per share for the current year.
A hedge fund recently raised its stake in Celsion Corp. stock. Sabby Management LLC raised its stake in shares of Celsion Corp. (NASDAQ:CLSN) by 7,986.5% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,519,365 shares of the company’s stock after buying an additional 1,500,576 shares during the period. Sabby Management LLC owned about 6.48% of Celsion Corp. worth $1,930,000 as of its most recent filing with the SEC. 15.19% of the stock is currently owned by institutional investors and hedge funds.
About Celsion Corp.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corp. and related companies with MarketBeat.com's FREE daily email newsletter.